

LUNG CANCER

FCDS 2013 Educational Webcast Series
September 19, 2013



Mayra Espino, BA, RHIT, CTR
Steven Peace, BS, CTR
FCDS QC Staff



Presentation Outline

- Overview of Lung Cancer
- Signs, Symptoms and Risk Factors
- Anatomy of the Lungs
- Histologic Types of Lung Cancer
- New Lung Cancer Screening Recommendations
- Multiple Primary and Histology Coding Rules Refresher
- Collaborative Stage Data Collection System (CSV02.04)
- C.S. Site Specific Factors
- NCCN/ASCO Treatment Guidelines by Stage
- Text Documentation

2

Overview



3


Definition of Lung Cancer

*Lung cancer or bronchogenic cancer is defined as a malignant tumor of the lung arising within the wall or epithelium of the bronchus



4

Incidence and Mortality Lung Cancer



5

Incidence and Mortality Lung Cancer


Estimated Number* of New Cancer Cases and Deaths by Sex
US & FL - 2013

➤ 228,190 new lung cancers	➤ 159,480 lung cancers deaths
➤ 118,080 new Male lung cancer	➤ 87,260 Male lung cancer deaths
➤ 110,110 new Female lung cancer	➤ 72,220 Female lung cancer deaths
➤ 17,960 FL new cases lung cancer	➤ 12,070 FL lung cancers deaths

*ACS Cancer Facts & Figures 2013


6

Cancer Death Rates* Among Men, US, 1930-2009




*Age-adjusted to the 2000 US standard population.
Source: US Mortality Data 1980-2009; US Mortality Volumes 1930-1959.
National Center for Health Statistics, Centers for Disease Control and Prevention.

Cancer Death Rates* Among Women, US, 1930-2009




*Age-adjusted to the 2000 US standard population.
Source: US Mortality Data 1980-2009; US Mortality Volumes 1930-1959.
National Center for Health Statistics, Centers for Disease Control and Prevention.

Lung Cancer Kills More People Than...



Source: American Cancer Society, Cancer Facts & Figures 2012

Trends in Tobacco Use and Lung Cancer Death Rates* in the US



*Age-adjusted to 2000 US standard population.
Source: Death rates: US Mortality Data, 1960-2008, US Mortality Volumes, 1930-1959, National Center for Health Statistics, Centers for Disease Control and Prevention. Cigarette consumption: US Department of Agriculture, 1900-2007.

Lung Cancer Survival by Stage

	All Stages	Local	Regional	Distant		All Stages	Local	Regional	Distant
Breast (female)	89	98	84	24	Ovary	44	92	72	27
Colon & rectum	64	90	70	12	Pancreas	6	23	9	2
Esophagus	17	38	20	3	Prostate	99	100	100	28
Kidney†	71	91	64	12	Stomach	27	62	28	4
Larynx	61	76	42	35	Testis	95	99	96	73
Liver*	15	28	10	3	Thyroid	98	100	97	54
Lung & bronchus	16	52	25	4	Urinary bladder*	78	70	33	6
Melanoma of the skin	91	98	82	15	Uterine cervix	68	91	57	16
Oral cavity & pharynx	62	82	57	35	Uterine corpus	82	95	67	16

*Rates are adjusted for normal life expectancy and are based on cases diagnosed in the SEER 13 areas from 2000-2008, followed through 2008.

†Includes renal pelvis. ‡Includes intrahepatic bile duct. §Rate for in situ cases is 96%.

Local: an invasive malignant cancer confined entirely to the organ of origin. Regional: a malignant cancer that 1) has extended beyond the limits of the organ of origin directly into surrounding organs or tissues, 2) involves regional lymph nodes by way of lymphatic system, or 3) has both regional extension and involvement of regional lymph nodes. Distant: a malignant cancer that has spread to parts of the body remote from the primary tumor either by direct extension or by discontinuous metastasis to distant organs, tissues, or via the lymphatic system to distant lymph nodes.

Source: Howlander N, Kooze AM, Kosch M, et al. (eds). SEER Cancer Statistics Review, 1975-2009. National Cancer Institute, Bethesda, MD, www.seer.cancer.gov/csr/1975_2009, 2012.

American Cancer Society, Surveillance Research 2013

Lung Cancer Survival by Stage

*The 5-year survival for small cell lung cancer (6%) is lower than that for non-small cell (18%).


*5-year survival rate for all stages combined is only 16%.

*Only 15% of lung cancers are diagnosed at a localized stage, for which the 5-year survival rate is 52%.

*1-year relative survival for lung cancer increased from 37% in 1975-1979 to 44% in 2005-2008, largely due to improvements in surgical techniques and combined therapies.

Cancer Facts & Figures 2013


Geographic Patterns in Lung Cancer Death Rates* by State, US, 2005-2009: **Males**



Cancer Facts & Figures 2013, *Age adjusted to the 2000 US standard population.
Source: US Mortality Data, National Center for Health Statistics, Centers for Disease Control and Prevention. American Cancer Society, Surveillance Research, 2013

13


Geographic Patterns in Lung Cancer Death Rates* by State, US, 2005-2009: **Females**



Cancer Facts & Figures 2013, *Age adjusted to the 2000 US standard population.
Source: US Mortality Data, National Center for Health Statistics, Centers for Disease Control and Prevention. American Cancer Society, Surveillance Research, 2013

14

Appalachia and Major U.S. Rivers




Poverty Rates in Appalachia, 2005-2009
<http://arc.gov>



Mississippi River, Ohio River, Missouri River
<http://voanews.com>

15

U.S. Adult Smoking Rates




Adult Smoking Rates
<http://www.cdc.gov>

16

Signs and Symptoms

Symptoms may include persistent cough, sputum streaked with blood, shortness of breath, wheezing, chest pain, voice change, and recurrent pneumonia or bronchitis, hoarseness, pain when swallowing, high pitched sound when breathing.



17


Signs and Symptoms

- *Persistent cough
- *Unexplained dyspnea (SOB)
- *Sputum with blood (Hemoptysis)
- *Excessive sputum production
- *Weight loss & fatigue & anorexia
- *Hoarseness or change in voice
- *Shoulder or other joint pain
- *Chest, back or arm pain
- *Recurring episodes of pleural effusion, pneumonia or bronchitis



18

Signs and Symptoms



<http://www.yalemedicalgroup.org/stw/images/36570.jpg>

19

Risk Factors


- * Cigarette smoking
- * Other tobacco smoking
- * Passive smoking - 2nd hand smoke
- * Occupational carcinogens
 - * Asbestos exposure
- * Residential carcinogens
 - * Radon exposure
- * Having had certain other cancers
- * Family member with lung cancer
- * Having had other lung disease
- * TB, bronchitis & emphysema
- * Nutritional deficiencies
- * Air pollution
- * Viruses



20

Tobacco Use

- * Smoking main contributor
- * Cigarette smoke contains over 69 known carcinogens
 - * Radioisotopes
 - * Nitrosamine
 - * Benzene
 - * Acetone
 - * Cadmium



<http://media-cache-ak0.pinimg.com/736x/01/cd/77/01cd77b17267eba08e08775b735391d.jpg>



<http://wordpress.com/cigarette>

21

Tobacco Use



Smoke without fire
Suck on an e-cigarette and it produces a cloud of nicotine-carrying vapour with none of the toxic by-products of burning tobacco.



<http://www.awesomevapor.com>

22


Radon Gas



<http://premierradon.net>

23

Radon Gas




<http://pillartopost.com/epa>

24

Asbestos

- Asbestos and lung cancer
- Asbestos and mesothelioma



<http://www.mesothelioma.com/asbestos-cancer>

25

Air and Water Pollution

- High levels of air pollution
- Drinking water containing high levels of arsenic




<http://www.bing.com/images/search?q=arsenic+water+arsenic+toxic&FORM=IRIS2>

26

Viruses

- Implicated viruses include Human Papilloma Virus (HPV), Simian Virus (SV40), cytomegalovirus (CMV).
- These viruses may effect the cell cycle allowing uncontrolled cell division



<http://abcnews.go.com/Health/story?id=4728594>

27


Lung Anatomy




<http://www.omnimedicalsearch.com/conditions-diseases/images/lung-cancer.jpg>

28

Lung Anatomy



<http://www.damav.com/mare/lung/>




<http://legacy.owensboro.kctcs.edu>

29

Lung Anatomy

- * C34.0 Main bronchus
- * C34.1 Upper lobe, lung
- * C34.2 Middle lobe, lung (right lung only)
- * C34.3 Lower lobe, lung
- * C34.8 Overlapping lesion
- * C34.9 Lung, NOS

* Source: SEER Training: ICD-O-3 Site Codes




30

Lung Anatomy

The **hilum** is the space in each lung where the bronchus and blood vessels enter the lung.


The **apex** is the rounded area at the top of each lung.



31


Lung Anatomy

The **lingula**, found only in the left lung, is a projection of the upper lobe of the left lung thought to be a remnant of an ancient middle lobe of the left lung.



32

Lung Anatomy Great Vessels



Source: Springer Images. Figure adapted from Atlas of Human Anatomy, 2nd ed. Contents of the superior and middle mediastinum. http://www.springerimages.com/images/MedicineAndPublicHealth/1-10.1007_378-1-60327-372-5_4-9

33


Lung Anatomy Laterality



- Code laterality for all lung sub-sites except carina
- Code the laterality for the lung in which the tumor originated
- Count cancer in both lungs as separate primaries unless metastasis from one side to the other is documented
- Always check that multiple pulmonary nodules are not metastasis from another primary site
- If both lungs have nodules or tumors and the lung of origin is not known, assign code 4.
- Diffuse bilateral lung nodules is the only time when laterality = 4
- Always check that multiple pulmonary nodules are not metastasis from another primary site

34


Lung Anatomy Regional Lymph Nodes



- * NX Regional lymph nodes cannot be assessed
- * NO No regional lymph node metastases
- * N1 Metastasis in **ipsilateral** peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension
- * N2 Metastasis in **ipsilateral** mediastinal and/or subcarinal lymph node(s)
- * N3 Metastasis in **contralateral** mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)

35


Lung Anatomy Regional Lymph Nodes



N1 is defined as metastasis in ipsilateral peribronchial (left side of diagram) and/or ipsilateral hilar lymph nodes (right side of diagram) and intrapulmonary nodes, including involvement by direct extension of the primary tumor.

36


Lung Anatomy Regional Lymph Nodes



N2 is defined as metastasis in ipsilateral mediastinal (left side of diagram) and/or subcarinal lymph node(s) (right side of diagram).

37


Lung Anatomy Regional Lymph Nodes



N3 is defined as metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s), whereas M1b is defined as distant metastasis (in extrathoracic organs), and this would include distant lymph nodes.

38


Lung Anatomy Pleural Effusion



M1a is defined as separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion. This is an image of tumor with malignant pleural effusion, lymph nodes.

39


Lung Anatomy Layers of the Pleura



A tumor that falls short of completely traversing the elastic layer of the visceral pleura is defined as PL0. A tumor that extends through the elastic layer is defined as PL1 and one that extends to the surface of the visceral pleura as PL2. Extension of the tumor to the parietal pleura is defined as PL3.

40

Lung Anatomy Metastatic Sites




<http://lungcancer.tibiosolutions.com/staging.html>

www.landbioscience.com

41

Types of Lung Cancer



<http://sciencedirect.com>

42

Lung Cancer Type

* World Health Organization (WHO) divides lung cancer into two major classes based on histology, therapy and prognosis.

* The main classes of lung cancer are:


➤ Small Cell Lung Cancer (SCLC)

➤ Non-Small Cell Lung Cancer (NSCLC)

- Large Cell Carcinoma
 - Large Cell Neuroendocrine Carcinoma
- Squamous Cell Carcinoma
- Adenocarcinoma
 - Bronchoalveolar Carcinoma


43

Lung Cancer Type



44


Lung Cancer Type



Wahbah M, et al. Ann Diagn Pathol. 2007; 110:89-96

45

Lung Cancer Type



Kenfield SA, Wei EK, Stampfer MJ, Rosner BA, Colditz GA (2008). Tobacco Control 17 (3): 198-204

46


Small Cell Lung Carcinoma (SCLC)

* A type of lung cancer made up of small, round cells.

* Small cell lung cancer is less common than non-small cell lung cancer

* Often grows more quickly

* The name is often shortened to SCLC. Another name for SCLC is oat cell cancer because the cancer cells may look like oats (Flat shape) when viewed under a microscope, grows rapidly and quickly spreads to other organs



47



Source: webmd.com

Non-Small Cell Lung Carcinoma (NSCLC)



Non-small cell lung cancer is divided into 3 subcategories

✓ Large cell carcinomas make up a group of cancers that look large and abnormal under a microscope.

✓ Squamous cell carcinoma originates in the thin, flat cells that line the passages of the respiratory tract.

✓ Adenocarcinoma begins in the cells that form the lining of the lungs.

* Non-Small Cell Lung Cancer is the most common type of Lung Cancer

* Is usually grows and spreads more slowly than small cell lung cancer

48


Non-Small Cell Lung Carcinoma (NSCLC)

- * Squamous or epidermoid (807.3)--least likely to recur after resection; frequently a central or bronchial lesion.
- * Adenocarcinoma (814.3)--usually slow-growing, but can metastasize widely; usually a peripheral lesion.
- * Bronchioloalveolar (82503)--a very specific subtype adenocarcinoma with a distinct characteristic presentation and behavior. These tumors arise in the alveolar sacs in the lungs.
- * Large cell carcinoma (80123)--also called giant cell or clear cell.
- * Other subtypes of adenocarcinoma are acinar, papillary, and mucinous.
- * Adenosquamous carcinoma (85603)--a specific histologic variant containing both epithelial (squamous and glandular (adeno-) cells
- * Carcinoids (824.3)--arise from neuroectoderm (which generates supporting structures of lung).
- * Melanomas, sarcomas and lymphomas may also arise in the lung.
- * Mesothelioma (905.3)--linked to asbestos exposure; usually involves the pleura, not the lung.
- * Non-small cell carcinoma (80463)--a general term used sloppily to separate small cell from the "non-small cell" types (such as adenocarcinoma, Squamous cell carcinoma, large cell, etc.).
- * Only use 80463 when there is no other type of non-small cell carcinoma contained in the source documents.


Source: FCDS Monthly Memo Nov 2003

49

Large Cell Carcinoma



- Incidence: 15%
- More often peripheral mass; either single or multiple masses; may be central
- Named for the large, round cells seen in this cancer
- Grow quickly and spread so usually are diagnosed in later stage




- Often grows to large tumor
- Growth rate: rapid growth

Source: <http://www.drugs.com/health-guide/large-cell-cancer-of-the-lung.html>

50

Squamous Cell Carcinoma




- Arises from bronchial epithelium (i.e. major bronchi), confined to bronchial wall with no lymph node metastases
- As growth occurs, cavitation may develop in lung distal to tumor.
- Tumor may occur in apex & upper respiratory zone
- Growth rate: slow growth

- Five year survival is 90% or more if no 2nd SCC present

Sources: Adam and Medline Plus

51

Adenocarcinoma



52

Adenocarcinoma

- Majority Arises from terminal bronchioles
- Tend to be located in the periphery of the lung
- Cancer that begins in the cells that line the alveoli and make substances such as mucous.
- 80% contain mucin
- A slow growing cancer that can take years to develop into invasive cancer
- Most common subtype in nonsmokers
- In US, 50% of lung carcinomas in women are adenocarcinoma

- Incidence: >40%

Clinical features

- May be associated with scarring
- Grows slower than SCC
- 5 year survival:
 - Stage I - 69%
 - Stage II - 40%
 - Stage IIIA - 17%
 - Stage IIIB - 5%
 - Stage IV - 8%

53

Adenocarcinoma

Gross description

- Poorly circumscribed gray-yellow lesions, single or multiple, may be mucoid
- 77% involve visceral pleura producing puckering/pleural retraction, 65% are peripheral
- Usually not cavitory
- Often associated with a peripheral scar or honeycombing (scar appears to be response to tumor)
- Rarely spreads into pleural space to coat visceral and parietal pleura and resemble diffuse mesothelioma



This is a peripheral adenocarcinoma of the lung


<http://www.pathologyoutlines.com>

54

Bronchoalveolar Adenocarcinoma

Travis Classification

- Adenocarcinoma in situ (AIS) (formerly Bronchioalveolar Carcinoma - BAC) which is a pre-invasive lesion
- Minimally invasive adenocarcinoma (MIA) <3cm nodule with <5mm invasion
- These neoplasms have a better prognosis than other lung cancers.
- Composed of columnar cells that proliferate along the framework of alveolar septae, a so-called "lepidic" growth pattern. The cells are well-differentiated



This is another type of adenocarcinoma of lung known as adenocarcinoma-in-situ (formerly called bronchoalveolar adenocarcinoma)

55 <http://www.pathologyoutlines.com>

Bronchoalveolar Adenocarcinoma




<http://cancergrace.org/lung>

- Under the microscope, an image such as that on the left shows thickened walls of the gas-exchanging sacs in the lungs called alveoli.
- The classic description of this pattern is *lepidic*, meaning "scale-like."
- X-rays and other imaging shows a picture that looks remarkably like pneumonia, as shown on the right.
- Patients with BAC are routinely diagnosed as having pneumonia for weeks or months before a diagnosis of cancer is actually established.

56

Lung Cancer Histology Groups



<http://stageiv.files.wordpress.com>

57

Lung Cancer Screening

Low Dose Helical CT (LDCT or also known as spiral CT)



<http://www.sdrad.com/patient-information/lung-cancer-screening.php>

58

Lung Cancer Screening

- * **August 2011 - National Lung Screening Trial (NLST) Results**
- * Screening with low-dose spiral CT compared to CXR reduced lung cancer deaths among older heavy smokers by 20%.
- * Improved detection of lung cancer at early stage is key to increased survival and improved mortality.
- * **Weigh Benefits/Risk** of lung cancer screening using CT scan
- * **Recommend Screening in High Risk Population:**
 - * Current/Former Smoker
 - * Age 55-74 Years
 - * Smoking History of at least 20-30 pack-years (varies by organization)
 - * No personal history of lung cancer
- * **Frequency of Screening - Annual**

59

Lung Cancer Screening

- * Endorsement/Adoption of Guideline
 - * American Cancer Society (ACS)
 - * American Lung Association (ALA)
 - * American College of Chest Physicians (ACCP)
 - * American Association for Thoracic Surgery (AATS)
 - * ASCO/NCCN Clinical Practice Guidelines (ASCO/NCCN)
 - * United States Preventative Services Task Force

60

Lung Cancer Workup

Endoscopic ultrasound (EUS)





Illustration www.health.uab.edu

CT-Guided Needle Aspiration Biopsy




<http://www.urmc.rochester.edu/encyclopedia>


67

Lung Cancer Workup

Thoracentesis



Thoracotomy



68

Lung Cancer Workup Biomarkers

*Data show that targeted therapy is potentially very effective in patients with specific gene mutations or rearrangements.

*Several biomarkers have emerged as prognostic (patient survival) and predictive (therapeutic efficacy) for NSCLC.

69

Lung Cancer Workup Biomarkers

***EGFR**

* Epidermal Growth Factor Receptor

***ERCC1**

* Endonuclease of the nucleotide excision repair complex

***K-ras** oncogene

***RRM1**

* Regulatory subunit of ribonucleotide reductase

***EML4-ALK Fusion Oncogene**

70

Lung Cancer Workup

Immunohistochemical Stains (IHC)

- TTF-1 is very important in distinguishing primary from metastatic adenocarcinoma.
- Most primary lung adenocarcinomas are TTF-1 positive.
- Squamous cell lung carcinomas are often TTF-1 negative
- Other squamous cell IHC tests - p63 positive and cytokeratin positive
- Other adenocarcinoma IHC tests - CEA, B72.3, BER-EP4, and MOC3.
 - These stains are negative for mesothelioma.
- Thyroglobulin is present in tumors from patients with thyroid cancer, but it is negative in lung cancer tumors.
- Pulmonary adenocarcinoma is usually CK7+ and CK20-, whereas metastatic adenocarcinoma of the colorectum is usually CK7- and CK20+.

NCCN Guidelines

71

Lung Cancer Workup

Small Cell Lung CA Biomarkers

*Nearly all SCLCs are immunoreactive for keratin, epithelial membrane antigen, and thyroid transcription factor-1 (TTF-1).

*Most SCLCs also stain positive for markers of neuroendocrine differentiation, including chromogranin A, neuron-specific enolase, neural cell adhesion molecule (NCAM; CD56) and synaptophysin.

*However, these markers alone cannot distinguish SCLC from NSCLC because approximately 10% of NSCLC will be immunoreactive for at least one of these neuroendocrine markers.

72

Lung MPH Rules Terms and Definitions



73

Lung Equivalent Terms, Definitions, Charts, Tables and Illustrations C340-C349 (Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

Introduction

Use these rules only for cases with primary lung cancer.

Lung carcinomas may be broadly grouped into two categories, small cell and non-small cell carcinoma.

Frequently a patient may have two or more tumors in one lung and may have one or more tumors in the contralateral lung. The physician may biopsy only one of the tumors. Code the case as a single primary (See Rule M1, Note 2) unless one of the tumors is proven to be a different histology. It is irrelevant whether the other tumors are identified as cancer, primary tumors, or metastases.

Equivalent or Equal Terms

- Low grade neuroendocrine carcinoma, carcinoid
- Tumor, mass, lesion, neoplasm (for multiple primary and histology coding rules only)
- Type, subtype, predominantly, with features of, major, or with ____ differentiation

Obsolete Terms for Small Cell Carcinoma (Terms that are no longer recognized)

- Intermediate cell carcinoma (B044)
- Mixed small cell/large cell carcinoma (B043) (Code is still used, however current accepted terminology is combined small cell carcinoma)
- Oct cell carcinoma (B042)
- Small cell anaplastic carcinoma (No ICD-O-3 code)
- Undifferentiated small cell carcinoma (No ICD-O-3 code)

Definitions

Adenocarcinoma with mixed subtype (B255): A mixture of two or more of the subtypes of adenocarcinoma such as acinar, papillary, bronchioalveolar, or solid with mucin formation.

Adenosquamous carcinoma (B560): A single histology in a single tumor composed of both squamous cell carcinoma and adenocarcinoma.

Bilateral lung cancer: This phrase simply means that there is at least one malignancy in the right lung and at least one malignancy in the left lung. Do not base multiple primary decisions on this phrase; bilateral does not mean this is a single primary. Use the multiple primary rules to decide whether to code bilateral lung cancers as a single or multiple primary.

Combined small cell carcinoma (B045): A small cell carcinoma that is combined with a non-small cell carcinoma. The combinations are small cell and adenocarcinoma, or squamous cell carcinoma, or large cell carcinoma.

Lung Terms and Definitions

Lung Equivalent Terms, Definitions, Charts, Tables and Illustrations C340-C349 (Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

Large cell carcinoma (B012): Large cell is a diagnosis that is used when the tumor is a non-small cell carcinoma that is undifferentiated. Because the tumor is undifferentiated, the pathologist cannot find glandular (adenocarcinoma) or squamous differentiation.

Large cell neuroendocrine carcinoma (B013): A non-small cell carcinoma with neuroendocrine differentiation proven by immunohistochemical stain, currently classified as large cell carcinoma. These tumors require further study before being included as a separate category in a histologic classification.

Most invasive: The tumor with the greatest continuous extension.

Neuroendocrine carcinoma (B246): Neuroendocrine carcinoma is a group of carcinomas that include typical carcinoid tumor and small cell carcinoma. Code the specific histology when given. Code neuroendocrine carcinoma, NOS (B246) when no specific histology is documented.

Non-small cell carcinoma (B046): The term non-small cell is used two ways, as a group term describing all carcinomas that are not small cell, and as a default diagnosis when there isn't enough tissue to classify the tumor beyond the exclusion of small cell.

Pancoast tumor: An anatomic designation (not a specific histology) for a lung cancer that starts in the upper lobe of the lung and extends outward to destroy the ribs and vertebrae. The tumor may compress or directly invade the brachial plexus (nerve bundles) of the neck, causing pain. Pancoast tumor may also be called superior sulcus tumor.

Pleomorphic carcinoma (B022): A poorly differentiated non-small cell carcinoma (squamous cell carcinoma, adenocarcinoma, or large cell carcinoma) containing spindle cells and/or giant cells or, a carcinoma containing only spindle cells and giant cells. These fall under the general category of sarcomatoid carcinoma.

Sarcomatoid carcinoma: A group of tumors that are non-small cell in type and contain spindle cells and/or giant cells. Depending on the histologic features the tumor may be designated: pleomorphic carcinoma (B022); spindle cell carcinoma (B032); giant cell carcinoma (B031); carcinosarcoma (B980); or pulmonary blastoma (B972).


Small cell carcinoma: Malignant epithelial tumor consisting of small cells. There are many types of lung cancer, but most can be categorized into one of two basic types, "small cell carcinoma" or "non-small cell carcinoma."

Undifferentiated carcinoma (B020): A high grade malignancy lacking glandular structures or other specific features that can be used to better classify the tumor. Undifferentiated carcinoma is used by pathologists when they believe the tumor is a carcinoma (not lymphoma, melanoma, or sarcoma) but they are not sure if the tumor is small cell or non-small cell.

Lung Equivalent Terms, Definitions, Charts, Tables and Illustrations C340-C349 (Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

Chart 1 – Lung Histology Groups and Specific Types

Note: This chart is based on the WHO Classification of Tumors for tumors of the lung. The chart is not a complete listing of histologies that may occur in the lung.



Lung MPH Rules Multiple Primary Rules




77

Lung Multiple Primary Rules - Flowchart

(C340-C349)
(Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.




** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.



Lung MP

January 1, 2007



111



Lung MPH Rules Histology Coding Rules



82



Lung


CS Extension

Collaborative Stage for TNM 7 - Revised 10/25/2011 | [Systems 1](#)

- Note 1: Direct extension to or other involvement of structures considered M1 in AJCC staging is coded in the data item CS Mets at DX. This includes: sternum; skeletal muscle; skin of chest; contralateral lung or mainstem bronchus; separate tumor nodules in contralateral lung.
- Note 2: Distance from Carina: Assume tumor is greater than or equal to 2 centimeters (cm) from carina if lobectomy, segmental resection, or wedge resection is done.
- Note 3: Collapse Lung: If no mention is made of the opposite lung on a chest x-ray, assume it is not involved.
- Note 4: Bronchopneumonia: Bronchopneumonia is not the same thing as obstructive pneumonitis and should not be coded as such. Bronchopneumonia is an acute inflammation of the walls of the bronchioles, usually a result of spread of infection from the upper to the lower respiratory tract. Obstructive pneumonitis is a combination of atelectasis, bronchiectasis with mucous plugging, and parenchymal inflammation that develops distal to an obstructing endobronchial lesion.
- Note 5: Pulmonary Artery/Vein: An involved pulmonary artery/vein in the mediastinum is coded to 700 (involvement of major blood vessels). However, if the involvement of the artery/vein appears to be only within lung tissue and not in the mediastinum, it is not coded to 700.
- Note 6: Vocal cord paralysis (resulting from involvement of recurrent branch of the vagus nerve), superior vena cava (SVC) obstruction, or compression of the trachea or the esophagus may be related to direct extension of the primary tumor or to lymph node involvement. The treatment options and prognosis associated with these manifestations of disease extent fall within the T4 Stage III category; therefore, generally use code 700 for these manifestations. However, if the primary tumor is peripheral and clearly unrelated to vocal cord paralysis, SVC obstruction, or compression of the trachea or the esophagus, code these manifestations as mediastinal lymph node involvement (code 200) in CS Lymph Nodes, unless there is a statement of involvement by direct extension from the primary tumor.
- Note 7: Pleural effusion and pericardial effusion are coded in CS Mets at DX.
- Note 8: In some cases, the determination of the T category for TNM 6 or 7 staging is based on this field. CS Tumor Size, CS Mets at DX, and CS Site-Specific Factor 1.
- Note 9: Code to the highest applicable code for CS Extension and then code the absence or presence of separate ipsilateral tumor nodules in CS Site-Specific Factor 1. Separate Tumor Nodule/Ipsilateral lung: Code separate tumor nodules in contralateral lung in CS Mets at DX.
- Note 10: Specific information about visceral pleura invasion is captured in codes 410-430 and CS Site-Specific Factor 2, Visceral Pleural Invasion (VPI)/Elastic Layer. Elastic layer involvement has prognostic significance for lung cancer.

Code	Description	TNM 7 Map	TNM 6 Map	SS77 Map	SS2000 Map
000	In situ, intraepithelial, noninvasive	A	A	B	**
100	Tumor confined to one lung WITHOUT extension or conditions described in codes 200-400 EXCLUDING primary in main stem bronchus EXCLUDING superficial tumor as described in code 110	A	A	L	**
110	Superficial tumor of any size with invasive component limited to bronchial wall with or without proximal extension to the main stem bronchus	A	A	L	**

CS and TNM



T1 is defined as a tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). T1a is defined as a tumor 2 cm or less in greatest dimension (upper left). T1a is also defined as a superficial spreading tumor of any size with its invasive component limited to the bronchial wall, which may extend proximally to the main bronchus (lower left). T1b is defined as a tumor more than 2 cm but 3 cm or less in greatest dimension (right).

92

CS and TNM

Code	Description	TNM 7 Map	TNM 6 Map	SS77 Map	SS2000 Map
000	In situ, intraepithelial, noninvasive	A	A	B	**
100	Tumor confined to one lung WITHOUT extension or conditions described in codes 200-400 EXCLUDING primary in main stem bronchus EXCLUDING superficial tumor as described in code 110	A	A	L	**
110	Superficial tumor of any size with invasive component limited to bronchial wall with or without proximal extension to the main stem bronchus	A	A	L	**
115	Stated as T1a with no other information on extension	A	A	L	**
120	Stated as T1b with no other information on extension	A	A	L	**
125	Stated as T1(NOS) with no other information on extension	A	A	L	**
200	Extension from other parts of lung to main stem bronchus, NOS EXCLUDING superficial tumor as described in code 110 Tumor involving main stem bronchus greater than or equal to 2.0 cm from carina (primary in lung or main stem bronchus)	A	A	L	**
210	Tumor involving main stem bronchus, NOS (Distance from carina not stated and no surgery as described in Note 2)	A	A	L	**

93



CS Ext – Code 100 vs 300

* Can you please clarify the difference between the two codes. For example, you are staging a case based on x-ray findings and the MD states there is a mass in RUL. He gives no further information on extension. I would think code 100 would apply. If so, when would be the proper time to use code 300?

* Code 100 is generally used when there is a tumor size and the lesion/mass is clearly confined to the lung. Code 300 would be used when you have limited information, such as this case. Do you have a size from the x-ray or any other type of report?

* If you can find a size, then you could use 100 with that size. Based on the information you have given, you would not get a T value on this case unless you can find a tumor size.

* Code 300 would also be used if the only information you had was "tumor confined to lung."


94

CS and TNM

Code	Description	TNM 7 Map	TNM 6 Map	SS77 Map	SS2000 Map
300	Localized, NOS	A	A	L	**
400	Atelectasis/obstructive pneumonitis that extends to the hilar region but does not involve the entire lung Or atelectasis/obstructive pneumonitis, NOS	A	A	RE	**
410	Extension to but not into pleura, including invasion of elastic layer BUT not through the elastic layer	A	A	RE	**
420	Invasion of pleura, including invasion through the elastic layer	A	A	RE	**
430	Invasion of pleura, NOS	A	A	RE	**
440	Pulmonary ligament	A	A	RE	**
450	OBsolete DATA RETAINED V0200 Extension to: Pleura, visceral or NOS (WITHOUT pleural effusion) Pulmonary ligament	ERROR	A	RE	**
455	Stated as T2a with no other information on extension	A	A	RE	**
460	Stated as T2b with no other information on extension	A	A	RE	**
465	Stated as T2 (NOS) with no other information on size or extension	A	A	RE	**
500	Tumor involving main stem bronchus less than 2.0 cm from carina	A	A	L	**

95

CS and TNM



96



Atelectasis Due to Pleural Effusion

- * 15mm mass in left lung apex highly suspicious for malignancy.
- * There is massive left sided pleural effusion with atelectasis and collapse of the left lung.
- * Would I use code 550 for CS Ext if atelectasis is caused by pleural effusion and the pleural effusion is malignant?
- * Extension code 550 is the appropriate code, based on the atelectasis and the collapse of the left lung
- * The pleural effusion, now coded in CS Mets at DX, would be code 15 since malignant pleural effusion is on the same side as the primary malignancy.

97

CS and TNM

Atelectasis


- * The collapse or closure of the lung resulting in reduced or absent gas exchange (not same as pneumothorax)
- * May affect part or all of one lung
- * May be acute or chronic
- * Respiratory distress

Bronchopneumonia

- * Acute inflammation of the walls of the bronchioles
- * Characterized by multiple foci of isolated, acute consolidation in one or more pulmonary lobules
- * **Consolidation** is the swelling (edema or inflammatory exudate) or hardening of the lung tissue


98

CS and TNM



99

Layers of the Pleura



A tumor that falls short of completely traversing the elastic layer of the visceral pleura is defined as PL0. A tumor that extends through the elastic layer is defined as PL1 and one that extends to the surface of the visceral pleura as PL2. Extension of the tumor to the parietal pleura is defined as PL3.


100

Pleural and Pericardial Effusion

720	<p>OBSOLETE DATA RETAINED V0200</p> <p>Pleural effusion reclassified as distant metastasis in AJCC 7th Edition, see CS Mets at DX code 15</p> <p>Malignant pleural effusion</p> <p>Pleural effusion, NOS</p>
760	<p>OBSOLETE DATA RETAINED V0200</p> <p>Separate pleural tumor foci reclassified as distant metastasis, see CS Mets at DX code 24</p> <p>Pleural tumor foci separate from direct pleural invasion</p>
790	<p>OBSOLETE DATA RETAINED V0200</p> <p>Pericardial effusion reclassified as distant metastasis, see CS Mets at DX code 20</p> <p>Pericardial effusion, NOS, malignant pericardial effusion</p>

101

CS and TNM



T3 includes separate tumor nodule(s) in the same lobe. T4 includes separate tumor nodule(s) in a different ipsilateral lobe.


102

CS and TNM

500	Invasion of phrenic nerve	A	*	RE	**
600	Direct extension to: Brachial plexus, inferior branches or NOS, from superior sulcus Chest (thoracic) wall Diaphragm Pancoast tumor (superior sulcus syndrome), NOS Parietal pleura Note: For separate lesion in chest wall or diaphragm, see CS Mets at DX.	A	*	D	**
610	Superior sulcus tumor WITH encasement of subclavian vessels OR WITH unequivocal involvement of superior branches of brachial plexus (CS or above)	T4	*	D	**
650	OBsolete DATA RETAINED V0200 Separate tumor nodules reclassified in AJCC 7th Edition, coded in CS SSF 1 Multiple masses/separate tumor nodule(s) in the SAME lobe "Satellite nodules" in SAME lobe	ERROR	*	L	**
680	Tumor confined to carina	T4	*	L	**
700	Blood vessels, major (EXCEPT aorta and inferior vena cava, see codes 740 and 770) Azygos vein Pulmonary artery or vein Superior vena cava (SVC syndrome) Carina from lung/mainstem bronchus Compression of esophagus or trachea not specified as direct extension Mediastinum, extrapulmonary or NOS Nerve(s) Cervical sympathetic (Horner syndrome)	T4	*	RE	**

103


CS and TNM



T4 is defined as tumor of any size that invades any of the following: mediastinum, heart, great vessels (upper right), trachea (upper left), recurrent laryngeal nerve, esophagus (lower right), vertebral body (lower left), carina (middle left and right), separate tumor nodule(s) in a different ipsilateral lobe

104


CS and TNM



T4 includes tumor invasion of the superior vena cava and heart.

105

CS and TNM



T4 includes tumor invasion of the aorta, esophagus, and vertebral body.

106

CS TS/Ext Eval

Lung	
CS Tumor Size/Ext Eval	
Code	Description
0	Does not meet criteria for AJCC pathologic staging. Evaluation based on physical examination, imaging examination, or other non-invasive clinical evidence. No surgical resection done.
1	Does not meet criteria for AJCC pathologic staging. Evaluation based on endoscopic examination, diagnostic biopsy, or other invasive techniques, including surgical exploration without biopsy. No surgical resection done.
2	Meets criteria for AJCC pathologic staging. Evidence derived from autopsy (tumor size suspected or diagnosed prior to autopsy). No surgical resection done.
3	Other meets criteria for AJCC pathologic staging. A. Surgical resection performed (with/without pre-surgical systemic treatment or radiation). On pathologic examination, evidence of local disease, treatment or evidence of distant disease (not documented as distant disease). B. No surgical resection done. Evaluation based on positive biopsy of highest T classification.
4	Does not meet criteria for AJCC pathologic staging. Surgical resection performed and T4S resected tumor, and tumor specimen based on clinical evidence, unless the pathologic evidence at surgery (or T4S resection) is more extensive (see code 5).
5	Meets criteria for AJCC pathologic staging. Surgical resection performed and T4S resected tumor AND tumor specimen based on pathologic evidence, because pathologic evidence at surgery is more extensive than clinical evidence before treatment.
6	Meets criteria for autopsy (A) staging. Evidence from autopsy only (tumor size, unexcised or unexcised prior to autopsy).
9	Unknown pathologic evidence. Not specified, pathologic assessment Unknown assessment Not documented in patient record

107

CS Lymph Nodes

Collaborative Study for TNM - Tumor (8805010) [2020/1]

Lung


CS Lymph Nodes

- Item 1: Item 1 only regional lymph nodes involved, N0, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 2: Item 2 only nodal involvement, no involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 3: Item 3 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 4: Item 4 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 5: Item 5 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 6: Item 6 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 7: Item 7 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 8: Item 8 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 9: Item 9 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 10: Item 10 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 11: Item 11 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 12: Item 12 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 13: Item 13 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 14: Item 14 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 15: Item 15 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 16: Item 16 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 17: Item 17 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 18: Item 18 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 19: Item 19 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 20: Item 20 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 21: Item 21 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 22: Item 22 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 23: Item 23 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 24: Item 24 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 25: Item 25 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 26: Item 26 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 27: Item 27 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 28: Item 28 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 29: Item 29 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 30: Item 30 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 31: Item 31 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 32: Item 32 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 33: Item 33 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 34: Item 34 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 35: Item 35 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 36: Item 36 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 37: Item 37 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 38: Item 38 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 39: Item 39 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 40: Item 40 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 41: Item 41 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 42: Item 42 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 43: Item 43 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 44: Item 44 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 45: Item 45 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 46: Item 46 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 47: Item 47 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 48: Item 48 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 49: Item 49 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 50: Item 50 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 51: Item 51 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 52: Item 52 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 53: Item 53 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 54: Item 54 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 55: Item 55 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 56: Item 56 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 57: Item 57 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 58: Item 58 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 59: Item 59 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 60: Item 60 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 61: Item 61 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 62: Item 62 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 63: Item 63 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 64: Item 64 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 65: Item 65 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 66: Item 66 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 67: Item 67 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 68: Item 68 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 69: Item 69 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 70: Item 70 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 71: Item 71 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 72: Item 72 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 73: Item 73 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 74: Item 74 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 75: Item 75 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 76: Item 76 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 77: Item 77 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 78: Item 78 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 79: Item 79 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 80: Item 80 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 81: Item 81 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 82: Item 82 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 83: Item 83 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 84: Item 84 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 85: Item 85 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 86: Item 86 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 87: Item 87 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 88: Item 88 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 89: Item 89 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 90: Item 90 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 91: Item 91 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 92: Item 92 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 93: Item 93 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 94: Item 94 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 95: Item 95 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 96: Item 96 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 97: Item 97 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 98: Item 98 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 99: Item 99 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 100: Item 100 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 101: Item 101 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 102: Item 102 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 103: Item 103 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 104: Item 104 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 105: Item 105 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 106: Item 106 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 107: Item 107 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 108: Item 108 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 109: Item 109 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 110: Item 110 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 111: Item 111 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 112: Item 112 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 113: Item 113 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 114: Item 114 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 115: Item 115 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 116: Item 116 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 117: Item 117 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 118: Item 118 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 119: Item 119 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 120: Item 120 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 121: Item 121 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 122: Item 122 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 123: Item 123 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 124: Item 124 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 125: Item 125 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 126: Item 126 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 127: Item 127 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 128: Item 128 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 129: Item 129 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 130: Item 130 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 131: Item 131 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 132: Item 132 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 133: Item 133 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 134: Item 134 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 135: Item 135 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 136: Item 136 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 137: Item 137 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 138: Item 138 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 139: Item 139 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 140: Item 140 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 141: Item 141 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 142: Item 142 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 143: Item 143 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 144: Item 144 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area of the lymph nodes (hilar nodes include N0, N1, N2, N3, also listed below, under no involvement of CS (see Item 10, for discussion of nodal stations, see Part 1)
- Item 145: Item 145 only nodal involvement of "hilar", "subcarinal", or "mediastinal" area

108

CS Lymph Nodes


REGIONAL LYMPH NODES



- * **NX** Regional lymph nodes cannot be assessed
- * **N0** No regional lymph node metastases
- * **N1** Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension
- * **N2** Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)
- * **N3** Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)

109

CS Lymph Nodes



- * **NX** Regional lymph nodes cannot be assessed
- * **N0** No regional lymph node metastases
- * **N1 Same side**
 - * Direct Extension
 - * Hilar lymph node(s)
 - * Intrapulmonary lymph node(s)
 - * Peribronchial lymph node(s)
- * **N2 Same side**
 - * Mediastinal lymph node(s)
 - * Subcarinal lymph node(s)
- * **N3 Contralateral**
 - * Hilar lymph node(s)
 - * Mediastinal lymph node(s)
 - * Any scalene lymph node(s)
 - * Any supraclavicular lymph node(s)

<http://www.chestandvascularsurgerypc.com/images/naruke.jpg>

110

Lung

CS Site-Specific Factor 1
Separate Tumor Nodules - Ipsilateral Lung

- Note 1. Separate tumor nodules in the ipsilateral lung are coded separately from CS Extension. Separate tumor nodules in the contralateral lung are coded in CS Mets at DX.
- Note 2. Separate tumor nodules can be defined clinically (by imaging) and/or pathologically.
- Note 3. If separate tumor nodules are not mentioned in imaging and/or pathological reports, use code 000.

Code	Description
000	No separate tumor nodules noted
010	Separate tumor nodules in ipsilateral lung, same lobe
020	Separate tumor nodules in ipsilateral lung, different lobe
030	020 + 010
040	Separate tumor nodules, ipsilateral lung, same and different lobe
050	Separate tumor nodules, ipsilateral lung, unknown if same or different lobe
888	OBsolete DATA CONVERTED V0308 See code 988 Not applicable for this site
988	Not applicable: Not collected for this case (May include cases converted from code 888 used in Cdv1 for "not applicable" or when the item was not collected. If this item is required to denote T, N, M, or any stage, use of code 988 may result in an error.)
999	Unknown if separate tumor nodules Separate tumor nodules cannot be assessed Not documented in patient record

111

Lung


CS Site-Specific Factor 2
Pleural/Elastic Layer Invasion (PL) by H and E or Elastic Stain

- Note 1: AACC Staging Manual 7th Edition includes a standardized and precise definition of pleuropneural tissue invasion (P3). There are two types of P3 invasion:
P3-1: Tumor that is surrounded by thin paramechria of chorion superficially into the pleural connective tissue between the elastic layer and the paramechria.
P3-2: Tumor that invades beyond the elastic layer.
P3-3: Tumor that arises in the surface of the vitelline vesicle.
P3-3: Tumor that invades the parietal chorion.
Note 2: P3-1 and P3-2 are considered pleural invasion for staging and are classified as at least a T2. P3-3 is classified as at least a T3. P3-3 is not considered pleural invasion for T1M staging, and the T category is assigned based on other criteria. Others can also cite P3-3 as pleural invasion.
Note 3: Pathologists have difficulty assessing the relationship of the tumor to the chorion on routine hematoxylin and eosin (H and E) slides. The following criteria are suggested:
Note 2: Note 2 criteria are stated on the pathology report. Code 908 of HSC histology: examination of pleura to assess pleural invasion.
Note 3: Note 3 criteria are stated on the pathology report. Code 909 of HSC histology: examination of chorion to assess chorion invasion.
Note 4: An FNA is not a histologic specimen and is not adequate to assess pleural tissue invasion. If only an FNA is available, use code 908 of HSC histology: examination of pleura to assess pleural invasion.
Note 5: An FNA is not a histologic specimen and is not adequate to assess chorion tissue invasion. If only an FNA is available, use code 909 of HSC histology: examination of chorion to assess chorion invasion.

Code	Description
000	PL 0 No evidence of visceral pleural invasion (PL 1) Tumor does not completely breach the elastic layer
010	PL 1 Invasion beyond the visceral elastic pleura, but limited to the pulmonary pleura Tumor extends through the elastic layer
020	PL 2 Invasion to the surface of the pulmonary pleura Tumor extends to the surface of the visceral pleura
030	PL 3 Tumor extends to the parietal pleura
040	Invasion of pleura, NOS
065	OBSOLETE DATA CONVERTED V2000 See code S8S
	Not applicable for this site
999	Not applicable - information not collected for this cause Main cause codes are converted from ICD-9 to ICD-10 in C14 for "full application" or unless the item was not collected. If this item is required to derive Y, N, M, or any stage, use of code S8S may result in an error.

112

Layers of the Pleura



A tumor that falls short of completely traversing the elastic layer of the visceral pleura is defined as PL0. A tumor that extends through the elastic layer is defined as PL1 and one that extends to the surface of the visceral pleural as PL2. Extension of the tumor to the parietal pleura is defined as PL3.

113


Parietal pleura (PL3)
Pleural space
Mesothelial cells on basement membrane (single layer) (PL2)
Submesothelial connective tissue (PL1)
Elastic fibers (Elastic layer) (single layer or double layer separated by fibrous connective tissue)
Connective tissue layer on thin basement membrane (PL0)
Lung parenchyma

Treatment Options



<http://livingwithcancerfacts.com>

114



115

Small Cell Lung Cancer

LIMITED STAGE

Any T
Any N
M0

Confined to Chest

Exception: T3-4 due to multiple lung nodules that do not fit in a tolerable radiation field

EXTENSIVE STAGE

Any T
Any N
M1a
M1b

Includes: T3-4 due to multiple lung nodules or tumor/nodal volume too large to be encompassed in a tolerable radiation plan

116

Small Cell Lung Cancer


LIMITED STAGE

- * Combination chemotherapy and radiation therapy to the chest.
- * Combination chemotherapy for patients with lung problems or who are very ill.
- * Surgery followed by chemotherapy or chemotherapy plus radiation therapy to the chest.
- * Clinical trials of new chemotherapy, surgery, and radiation treatments

EXTENSIVE STAGE

- * Combination chemotherapy.
- * Radiation therapy to the brain, spine, bone, or other parts of the body where the cancer has spread, as palliative therapy to relieve symptoms and improve quality of life.
- * Clinical trials of new chemotherapy treatments.

117



118

Lung Treatment Options by Stage

Stage I Non-Small Cell Lung Cancer

- Surgery (wedge resection, segmental resection, sleeve resection, or lobectomy).
- External radiation therapy (for patients who cannot have surgery or choose not to have surgery).
- A clinical trial of chemotherapy or radiation therapy following surgery.
- A clinical trial of surgery followed by chemoprevention.
- A clinical trial of treatment given through an endoscope, such as photodynamic therapy (PDT).

119

Lung Treatment Options by Stage

Stage II Non-Small Cell Lung Cancer

- Surgery (wedge resection, segmental resection, sleeve resection, lobectomy, or pneumonectomy).
- Chemotherapy followed by surgery.
- Surgery followed by chemotherapy.
- External radiation therapy (for patients who cannot have surgery or choose not to have surgery).
- A clinical trial of radiation therapy following surgery.

120

Non-Small Cell Lung Cancer

Source: National Cancer Institute Cancer Topics NSCLC

Stage (TNM Staging Criteria)	Standard Treatment Options
Occult NSCLC	Surgery
Stage 0 NSCLC	Surgery
	Endobronchial therapies
Stage I NSCLC	Surgery
	Radiation therapy
Stage II NSCLC	Surgery
	Neoadjuvant chemotherapy
	Adjuvant chemotherapy
	Radiation therapy

121

Lung Treatment Options by Stage:

Stage IIIA Non-Small Cell Lung Cancer

- Surgery followed by chemotherapy.
- Chemotherapy followed by surgery.
- Surgery followed by chemotherapy combined with radiation therapy.
- Surgery followed by radiation therapy.
- A clinical trial of new combinations of treatments

122

Lung Treatment Options by Stage

Cancer Cannot be Removed w/ Surgery

- Chemotherapy and radiation therapy given as separate treatments over the same period of time.
- External radiation therapy alone (for patients who cannot be treated with combined therapy, as palliative treatment to relieve symptoms / improve quality of life).
- Internal radiation therapy or laser surgery, as palliative treatment to relieve symptoms and improve the quality of life.
- A clinical trial of new combinations of treatments

123

Non-Small Cell Lung Cancer

Source: National Cancer Institute Cancer Topics NSCLC

Stage (TNM Staging Criteria)	Standard Treatment Options
Stage IIIA NSCLC	Resected or resectable disease
	Surgery
	Neoadjuvant therapy
	Adjuvant therapy
	Unresectable disease
	Radiation therapy
	Chemoradiation therapy
	Superior sulcus tumors
	Radiation therapy alone
	Radiation therapy and surgery
Chest wall tumors	Concurrent chemotherapy with radiation therapy and surgery
	Surgery alone (for selected patients)
	Surgery
	Surgery and radiation therapy
	Chemotherapy combined with radiation therapy and/or surgery

124


Non-Small Cell Lung Cancer

Source: National Cancer Institute Cancer Topics NSCLC

Stage (TNM Staging Criteria)	Standard Treatment Options
Stage IIIB NSCLC	Sequential or concurrent chemotherapy and radiation therapy
	Chemotherapy followed by surgery (for selected patients)
	Radiation therapy alone
	Combination chemotherapy
Stage IV NSCLC	Combination chemotherapy with bevacizumab or cetuximab
	Epidermal growth factor receptor tyrosine kinase inhibitors (for patients with EGFR mutations)
	Maintenance therapy following first-line chemotherapy
	External-beam radiation therapy (for palliation)
	Endobronchial laser therapy and/or brachytherapy (for obstructing lesions)


125

Coding Lung Cancer Surgery



126


Surgical Removal



<http://www.cts.usc.edu>

127

Surgical Removal



Wedge or Segmental Resection

Removal of one or more lung segment

Lobectomy

Removal of entire lobe of the lung

Pneumonectomy

Removal of entire lung

Note: If a lobectomy was performed, assume that the tumor was more than 2 cm distal to the carina.

128

Surgery Codes DAM Appendix F

SURGERY OF PRIMARY SITE

Codes

- 00 None, **no surgery of primary site; autopsy ONLY**
- 19 Local tumor destruction or excision, NOS
Unknown whether a specimen was sent to pathology for surgical events coded 19
No specimen sent to pathology from surgical events 12-13 and 15
- 15 Local tumor destruction, NOS
 - 12 Laser ablation or cryosurgery
 - 13 Electrocautery, fulguration (includes use of hot forceps for tumor destruction)
- 20 Excision or resection of less than one lobe, NOS
 - 23 Excision, NOS
 - 24 Laser excision
 - 25 Bronchial sleeve resection ONLY
 - 21 Wedge resection
 - 22 Segmental resection, including lingulectomy
- 30 Resection of [at least one] lobe or bilobectomy, but less than the whole lung (partial pneumonectomy, NOS)
The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery*
33 Lobectomy WITH mediastinal lymph node dissection
The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #872).
- 45 Lobe or bilobectomy extended, NOS
 - 46 WITH chest wall
 - 47 WITH pericardium
 - 48 WITH diaphragm

129

Surgery Codes DAM Appendix F

- 55 Pneumonectomy, NOS
[NOTE: Code 55 includes complete pneumonectomy, Sleeve pneumonectomy, Standard pneumonectomy, Total pneumonectomy, Resection of whole lung]
- 56 WITH mediastinal lymph node dissection (radical pneumonectomy)
The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #872).
- 65 Extended pneumonectomy
- 66 Extended pneumonectomy plus pleura or diaphragm
- 70 Extended radical pneumonectomy
The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #872).
- [NOTE: An extended radical pneumonectomy is a radical pneumonectomy (including removal of mediastinal nodes) and the removal of other tissues or nodes]
- 80 Resection of lung, NOS
Specimen sent to pathology from surgical events 20-80.
- 90 Surgery, NOS
- 99 Unknown if surgery performed, death certificate ONLY

130

Text Documentation



- Avoid non-standard text
- Keep it simple
- No repetition
- Justify coded items
- FCDS DAM Appendix L

- DEFENSIVE ABSTRACTING
- CYA-Cover your abstract

- Support ALL codes and dates with text - primary site, histology, staging workup, tumor size, nodal status, stage of disease, first course of RX

131

Text Documentation

- **Date(s)** - include date(s) references
- this allows the reviewer to determine event chronology
- **Date(s)** - note when date(s) are estimated [i.e. Date of DX 3/15/2011 (est.)]
- **Location** - include facility/physician/other location where the event occurred (test/study/treatment/other)
- **Abbreviated text** - Be brief but complete - use abbreviations correctly.
- **Text fields** If information is missing from the record, state that it is missing type not available (NA)
- **Edit your text documentation**
- **DO NOT REPEAT INFORMATION** from section to section
- **Operative text** - DO NOT enter the pathology info in the Op TEXT
Ex 8/26/12 ABC Facility Liver biopsy this should be part of pathology
- **Pathology text** -
Example 8/26/12 ABC facility Liver biopsy metastatic adenocarcinoma

132

References

- * National Cancer Institute
- * FCDS Data Acquisition Manual
- * American Society of Clinical Oncology
- * American Society for Radiation Oncology
- * 2013 Cancer Facts and Figures, American Cancer Society
- * Collaborative Stage Data Collection System
- * 2007 MPH Rules for Solid Tumors
- * National Lung Screening Trial (NLST)

133

Questions



http://media.mlive.com/health_impact/photo/9057757-large.jpg

134